Grant: Engage Plus Grants Program
Université de Montréal
$12,500.00
Development of a nystatin nanosuspension formulation using high pressure homogenisation
EF 2015-16
Résumé
Nystatin is the current treatment of choice for Oropharyngeal candidiasis (OPC), a common fungal infection of
the oral cavity. Poorly soluble nystatin is formulated as a suspension intended for local application. The
bioavailability of the active ingredient after oral administration is limited and principally eliminated in the
faeces. Nanosizing of poorly soluble drugs has been reported as an attractive approach to improve their efficacy
after oral administration. A previous publication showed that nanosizing provides a promising approach to
increasing the efficacy of topically administered nystatin in the treatment of OPC. A foregoing formulation
screening of nystatin using three different nanomilling processes showed that high pressure homogenisation
technique offered a better milling yield than the wet milling while the size of 90% of particles in the obtained
suspension were smaller than 1.9 µm.
The goal of the present project is to explore new formulations of nystatin suspension in order to obtain better
results in terms of particle size and physical stability, using the high pressure homogeniser. The new
formulations will be compared with the commercial nystatin suspension milled in the same conditions. The
chemical stability, the physicochemical stability, the presence of residual contamination and the nanoparticle
aggregation will be assessed during the long-term stability study of the promising formulation of nystatin
nanosuspension.
Programme
Engage Plus Grants Program
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
486974-2015
Name nom
Leclair, Grégoire
Department département
Pharmacie, faculté de
Organization id
63
Institution établissement
Université de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2015
Competition year année de concours
2015
Award amount
12500
Program id
EGP2
Program name en
Engage Plus Grants Program
Program name fr
Programme de subvention d'engagement partenarial Plus
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1552
Committee name en
Quebec Internal Decision Committee
Committee name fr
Comité de décision interne pour le Québec
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
1800
Research subject group en
Chemical engineering
Research subject group fr
Génie chimique
Research subject en
Chemical engineering
Research subject fr
Génie chimique
Partie
1
Nb partie
1
Application title
Development of a nystatin nanosuspension formulation using high pressure homogenisation
Keyword
NSERC
Application summary
Nystatin is the current treatment of choice for Oropharyngeal candidiasis (OPC), a common fungal infection of
the oral cavity. Poorly soluble nystatin is formulated as a suspension intended for local application. The
bioavailability of the active ingredient after oral administration is limited and principally eliminated in the
faeces. Nanosizing of poorly soluble drugs has been reported as an attractive approach to improve their efficacy
after oral administration. A previous publication showed that nanosizing provides a promising approach to
increasing the efficacy of topically administered nystatin in the treatment of OPC. A foregoing formulation
screening of nystatin using three different nanomilling processes showed that high pressure homogenisation
technique offered a better milling yield than the wet milling while the size of 90% of particles in the obtained
suspension were smaller than 1.9 µm.
The goal of the present project is to explore new formulations of nystatin suspension in order to obtain better
results in terms of particle size and physical stability, using the high pressure homogeniser. The new
formulations will be compared with the commercial nystatin suspension milled in the same conditions. The
chemical stability, the physicochemical stability, the presence of residual contamination and the nanoparticle
aggregation will be assessed during the long-term stability study of the promising formulation of nystatin
nanosuspension.